MZe-miR

MZe-miR is a preclinical-stage therapeutic candidate developed by Mirzyme Therapeutics. It is classified as a gut microbiota-based drug and is being investigated primarily for the treatment of congenital disorders, with a specific focus on fetal growth retardation and urogenital diseases. The precise mechanism of action, molecular target, and detailed modality are not publicly disclosed; however, its classification as "gut microbiota" suggests it may involve modulation of the intestinal microbial environment or delivery of microbe-derived molecules to influence host physiology[1]. As of May 2025, no clinical trial data or regulatory approvals have been reported.